Novozymes Past Earnings Performance

Past criteria checks 3/6

Novozymes hat die Erträge mit einer durchschnittlichen jährlichen Rate von 1.8% gesteigert, während die Branche Chemicals die Erträge growing mit 18.4% jährlich steigerte. Die Einnahmen sind growing mit einer durchschnittlichen Rate von 4.9% pro Jahr gestiegen. Novozymes Die Eigenkapitalrendite des Unternehmens beträgt 21.6%, und die Nettomargen liegen bei 18%.

Key information

1.5%

Earnings growth rate

2.5%

EPS growth rate

Chemicals Industry Growth	13.1%
Revenue growth rate	5.4%
Return on equity	21.2%
Net Margin	16.9%
Next Earnings Update	03 May 2024

Recent past performance updates

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Feb 14

Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?

Jan 01

We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt

Nov 28

Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital

Nov 11

Is Novozymes A/S (CPH:NZYM B) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 25

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Aug 23

Revenue & Expenses Breakdown
Beta

How Novozymes makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:NSIS B Revenue, expenses and earnings (DKK Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 23	17,899	3,024	3,325	2,017
30 Sep 23	17,825	3,209	3,291	2,013
30 Jun 23	17,736	3,425	3,319	2,027
31 Mar 23	17,805	3,628	3,284	2,010
31 Dec 22	17,553	3,676	3,198	1,986
30 Sep 22	16,858	3,418	3,292	1,951
30 Jun 22	16,252	3,108	3,108	1,911
31 Mar 22	15,546	3,093	2,995	1,912
31 Dec 21	14,951	3,146	2,828	1,982
30 Sep 21	14,563	3,175	2,492	1,995
30 Jun 21	14,233	3,044	2,397	2,037
31 Mar 21	14,002	2,895	2,308	2,008
31 Dec 20	14,012	2,825	2,299	1,905
30 Sep 20	14,297	3,093	2,303	1,850
30 Jun 20	14,570	3,020	2,431	1,893
31 Mar 20	14,679	3,273	2,497	1,968
31 Dec 19	14,374	3,154	2,459	1,966
30 Sep 19	14,357	3,069	2,492	1,959
30 Jun 19	14,311	3,238	2,398	1,939
31 Mar 19	14,351	3,116	2,351	1,859
31 Dec 18	14,390	3,226	2,334	1,852
30 Sep 18	14,349	3,183	2,322	1,897
30 Jun 18	14,271	3,194	2,308	1,837
31 Mar 18	14,311	3,154	2,382	1,849
31 Dec 17	14,531	3,119	2,470	1,901
30 Sep 17	14,572	3,131	2,486	1,895
30 Jun 17	14,382	3,063	2,468	1,887
31 Mar 17	14,273	3,077	2,439	1,866
31 Dec 16	14,142	3,050	2,414	1,865
30 Sep 16	13,880	2,936	2,434	1,841
30 Jun 16	14,012	2,929	2,477	1,880
31 Mar 16	14,032	2,861	2,464	1,931
31 Dec 15	14,002	2,823	2,462	1,896
30 Sep 15	13,731	2,734	2,390	1,906
30 Jun 15	13,393	2,630	2,342	1,878
31 Mar 15	13,005	2,539	2,324	1,812
31 Dec 14	12,459	2,526	2,276	1,766
30 Sep 14	12,218	2,484	2,338	1,688
30 Jun 14	11,970	2,413	2,311	1,614
31 Mar 14	11,934	2,379	2,332	1,577
31 Dec 13	11,746	2,200	2,321	1,528
30 Sep 13	11,617	2,132	2,253	1,533
30 Jun 13	11,519	2,085	2,283	1,536

Qualität der Erträge: NZYM B hat hohe Qualitätseinkünfte.

Wachsende Gewinnspanne: NZYM BDie aktuellen Gewinnspannen (16.9%) sind niedriger als im letzten Jahr (20.9%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Ergebnisentwicklung: NZYM BIn den letzten 5 Jahren sind die Gewinne von 1.8% jährlich gestiegen.

Beschleunigtes Wachstum: NZYM BDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: NZYM B hatte im vergangenen Jahr ein negatives Gewinnwachstum (-17.7%), was einen Vergleich mit dem Branchendurchschnitt Chemicals (-17.8%) erschwert.

Return on Equity

Hohe Eigenkapitalrendite: NZYM BDie Eigenkapitalrendite des Unternehmens (21.6%) wird als hoch angesehen.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Novozymes Past Earnings Performance

Past criteria checks 3/6

Key information

Recent past performance updates

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Full year 2023 earnings: Revenues in line with analyst expectations

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Third quarter 2023 earnings: Revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Nine Months, 2023 Results on Oct 26, 2023

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Novozymes Extends the Lifetime of Textiles with Sustainable Innovation

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Novozymes A/S Raises Full-Year Financial Guidance for 2022

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Upcoming dividend of kr.5.50 per share

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Revenue & Expenses Breakdown
Beta